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Background: L-carnitine is an essential compound that facilitates the transport of long-chain fatty acid across the
inner mitochondrial membrane for β-oxidation. However, the effect of L-carnitine supplementation remains to be
fully explored in patients with chronic kidney disease. We aimed in this study to determine the multidirectional
effects of L-carnitine supplementation on clinical parameters in more detail.
Methods: We orally administered L-carnitine to maintain serum-free carnitine levels within the normal range (30 to
70 μmol/L) for 6 months in 21 hemodialysis (HD) patients (age, 74 ± 11 years; time on HD, 60 ± 84 months).
Results: L-carnitine supplementation significantly increased serum transferrin from 155 ± 41 to 175 ± 48 mg/dL
(p < 0.01) and retinol-binding protein from 8.9 ± 2.5 to 10.0 ± 3.4 mg/dL (p < 0.05). The triceps skinfold thickness
was also significantly increased (p < 0.05), while the skeletal muscle mass in limbs and handgrip strength was
not. L-carnitine enhanced natural killer (NK) cell activity at the E (effector cell)/T (target cell) ratio of 20:1 from
17.3 ± 14.1 to 20.8 ± 17.7 % (p < 0.01). In addition, L-carnitine improved left ventricular functional shortening (p < 0.01)
with a significant decrease of brain natriuretic peptide (BNP) from 621.4 ± 666.8 to 412.0 ± 426.0 pg/mL (p < 0.05).
Conclusions: These findings suggest that oral L-carnitine treatment improves immunological and cardiac markers in
HD patients. In contrast, L-carnitine did not change the skeletal mass-related parameters during the 6-month follow-up.
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Protein-energy wasting (PEW) comprises excessive
losses of body protein mass and energy reserves, and it
is associated with high morbidity and mortality in pa-
tients with chronic kidney disease (CKD) [1]. There are
many causes of PEW such as inadequate nutrient intake,
increased nutrient losses from the dialysate, inflamma-
tion, oxidant stress, carbonyl stress, disorders of anabolic
or catabolic hormones, and acidemia [1].
L-carnitine is a natural compound that is synthesized
from lysine and methionine. L-carnitine is essential in* Correspondence: z011028sangyo@yahoo.co.jp
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dria for β-oxidation. When carnitine deficiency develops,
long-chain fatty acids are not available for β-oxidation or
energy production, which causes excessive lipid accumu-
lation in organs such as the muscle. Carnitine is also
necessary to maintain the function and morphology of
the brown adipose tissue [2]. Approximately 95 % of the
carnitine pool is present in the skeletal and cardiac
muscle, 2–3 % in the liver and kidneys, and only 0.5–
1 % in extracellular fluid [3].
Dialysis patients are especially at high risk for carnitine
deficiency due to poor intake of sources of dietary carni-
tine such as red meat, reduced biosynthesis in the kid-
neys, and diffusive loss from the dialysate. In incident
hemodialysis (HD) patients, the plasma carnitine level
decreases within the first week of the treatment, with adistributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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[4]. The carnitine content of the skeletal muscle also
decreases in hemodialysis patients and is inversely corre-
lated with time on HD [4, 5].
Metabolism of skeletal muscle is carnitine-dependent
because fatty acid oxidation is the main source of energy
in the muscular cells. However, it remains to be fully
determined whether or not L-carnitine supplementation
improves muscle power, physical capacity, and muscular
symptoms.
The aim of the present study is to further clarify the
effect of L-carnitine supplementation on clinical parame-
ters in HD patients. We prospectively administered L-
carnitine orally to maintain free carnitine levels within
the normal range for 6 months and examined the impact
of L-carnitine supplementation on nutritional, immuno-




This study was conducted in a single dialysis center
(National Hospital Organization Yanai Medical Center,
Yamaguchi, Japan). At first, 26 HD patients, who had
given their consent, were enrolled in this study. There
was no patient who had received any L-carnitine supple-
mentation before the entry. The study design had been
approved by the appropriate ethics review boards of the
institution within which the study was undertaken, and
it conformed to the provisions of the Declaration of
Helsinki.
All patients had been subjected to regular HD using
polysulfone dialyzer membranes with bicarbonate buffers
for 3 to 4 h three times per week.
L-carnitine supplementation
We originally modified the initial dose of oral L-carnitine
according to dry weight (DW) to maintain serum
level within normal range without risk, since excess
L-carnitine can be converted by intestinal microbiota into
trimethylamine-N-oxide (TMAO), a potential promoter
of coronary arteriosclerosis [6]. When DW was higher
than 50 kg, we initially administered 400 mg/day once a
day, while when DW ranged from 30 to 50 kg, we admin-
istered 300 mg/day. Also, if DW was less than 30 kg, we
started with the dose of 200 mg/day.
We then measured predialysis serum carnitine levels
every month for the initial 3 months. When the total
carnitine concentration exceeded the normal upper limit
(≥70 μmol/L), we decreased the dose by 100 mg daily
until the next measurement. In contrast, when the
serum level of total carnitine was less than the lower
limit (<30 μmol/L), we increased the dose by 100 mg/day
until the next measurement.Blood sampling and laboratory examinations
Blood samples were drawn from the arterial site of
the arteriovenous fistula at each dialysis session after
a 2-day interval at 0, 3, and 6 months after the en-
rollment. Blood cell counts, blood urea nitrogen,
serum creatinine, total protein, albumin, C-reactive
protein (CRP), lipids (low-density lipoprotein (LDL)
cholesterol, high-density lipoprotein (HDL) cholesterol,
and triglycerides), hemoglobin, ammonia, and brain natri-
uretic peptide (BNP) were measured by standard labora-
tory techniques using an auto-analyzer. We calculated
Kt/V for urea using a single pool kinetic model [7].
We also measured systolic and diastolic blood pres-
sure just before the start of HD.
Immunoglobulin (Ig), transthyretin, transferrin, retinol-
binding protein, free fatty acid, ceruloplasmin, β2-
microglubulin, and intact parathyroid measurement were
entrusted to Bio-Medical Laboratories, Inc. (Tokyo,
Japan). Total, free, and acylcarnitine were also measured
by enzyme cycling methods. Serum interleukin-6 (IL-6)
was determined with a Quantikine ELISA kit (R&D
Systems, Inc., Minneapolis, MN, USA).
Natural killer (NK) cell activity was measured using a
standard 51Cr release assay against K562 (a highly un-
differentiated and granulocytic myelogenous leukemia
cell line from blast crisis) as reference target cells
with 6-h incubation. NK activity was expressed as the
E (effector cell)/T (target cell) ratio (reference ranges;
E:T ratio = 20:1: 17.1–48.7 % and E:T ratio = 10:1:
8.9–29.5 %). Cluster of differentiation (CD) 4/CD8
was implemented by flow cytometry with the use of
FACSCalibur™ (BD Biosciences, San Jose, CA, USA)
and KX-21 (Sysmex, Kobe, Japan). Serum soluble
interleukin-2 receptor (IL-2R) was also measured
using enzyme-linked immunoassay kits (reference, 122–
496 U/mL).
The serum selenium, zinc, and copper levels were
measured by atomic absorption spectrophotometry
(reference ranges; selenium, 107–171 μg/dL; zinc, 59–
135 μg/dL; and copper, 66–130 μg/dL).
Nutritional assessment
Ideal body weight (BW) was defined as that calculated
from the patients’ heights using a body mass index
(BMI) of 22.0 kg/m2. BMI was calculated as dry
weight in kilograms divided by the square of the
height in meters. We calculated Onodera’s prognostic
nutrition index (PNI) using serum albumin, total lympho-
cytes (TLC), and dry BW as follows: PNI = [10 × albumin
(g/dL)] + [0.005 × TLC] [8]. We also determined geriatric
nutritional risk index (GNRI) as follows: GNRI = [14.89 ×
albumin (g/dL)] + [41.7 × dry/ideal BW]. When DW was
greater than the ideal weight, GNRI was calculated as a
DW/ideal BW ratio identical to 1.0 [9].
Table 1 Characteristics of the study population
No. 21
Duration of hemodialysis (months) 60 ± 84
Age (years) 73.5 ± 11.6
Gender (male/female) 12/9
Dry weight (kg) 48.0 ± 12.5
Body height (cm) 158.0 ± 10.5
BMI (kg/m2) 19.0 ± 3.2
Comorbidity
Cardiovascular disease (%) 23.8
Cerebral vascular disease (%) 19.0
HCV Ab-positivity (%) 19.0
Laboratory parameters
Blood urea nitrogen (mg/dL) 47.5 ± 15.5
Creatinine (mg/dL) 6.9 ± 2.8
β2-MG (mg/L) 25.0 ± 8.1
Intact PTH (pg/mL) 90 ± 88
Data, means ± SD
BMI body mass index, HCV Ab anti-hepatitis C antibody, β2-MG β2-microglobulin,
PTH parathyroid hormone, SD standard deviation
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(nPCR) and percentile creatinine generation rate (%CGR),
which can estimate dietary protein intake and skeletal
muscle mass, respectively [7, 10].
Anthropometric parameters
At the start and end of the study, we measured the mid-
arm circumference (MAC) and triceps skinfold thickness
(TSF) using skinfold calipers on the limb not used for
vascular access after a HD session. We calculated the
midarm muscle circumference (MAMC) using MAC
and TSF as follows: MAMC =MAC – (TSF × 3.14). All
measurements were performed by the same trained
researcher.
We also determined the thigh muscle area by com-
puted tomography (CT; Aquilion ONE TSX-301A,
Toshiba, Tokyo, Japan). Each patient was examined in
the supine position with the thigh muscle relaxed. An
axial CT image was obtained at the midpoint of a line
extending from the superior border of the patella to the
greater trochanter of the femora. The thickness of the
slice was 10 mm. The thigh muscle area and bone area
in the thigh were determined using SCFM-001A soft-
ware (Toshiba, Tokyo, Japan). We used the standardized
thigh muscle area (TMA) divided by the thigh bone area
(TBA) to avoid the influence of body size, a surrogate
marker of thigh sarcopenia [11].
Handgrip strength
We measured handgrip strength on the upper part of
the arm not used for vascular access just before a
HD session using a Smedley handgrip dynamometer.
Each patient made two maximum force attempts,
with an interval of at least 1 min between attempts.
The highest recording was taken as the handgrip
strength reading.
M-mode echocardiography
M-mode echocardiography was conducted on a non-
dialysis day at study entry and at 6 months. All mea-
surements were conducted by the same trained
physician.
Left ventricular systolic function was assessed as
ejection fraction (EF) and fractional shortening (FS).
EF and FS were calculated as follows: EF (%) = (left
ventricular end-diastolic volume (LVEDV) − left ven-
tricular end-systolic volume (LVESV)) / LVEDV × 100
and FS (%) = (left ventricular end-diastolic dimension
(LVDd) − left ventricular end-systolic dimension (LVDs)) /
LVDd × 100.
Left ventricular mass (LVM) was calculated as fol-
lows: LVM (g) = 1.04 × [(LVDd + interventricular septum
(IVS) + left ventricular posterior wall end-diastolic thick-
ness (LVPW))3 − LVDd3] − 14. LVM was adjusted as to thebody surface area in square meters and expressed as the
left ventricular mass index (LVMI).Chest X-ray
The cardiothoracic ratio (CTR) was measured on a chest
X-ray just before HD therapy by a trained researcher.Statistical analysis
For statistical analysis, JMP (Version 11.1.1, SAS
Institute, Cary, NC, USA) was used. Descriptive results
were expressed as the means ± standard deviation (SD).
Parametric analyses were performed using Student’s t-test,
and the Wilcoxon t test was used for non-parametric
analyses. A value of p < 0.05 was considered statistically
significant different.Results
Basal characteristics
During the follow-up, since we had lost five patients due
to death (n = 4) and acute infection (n = 1), we finally
analyzed a total of 21 patients.
Table 1 presents the basal characteristics. The mean
age was 73.5 ± 11.6 years old, with an average time on
HD of 60 ± 84 months. The causes of end-stage kid-
ney disease were as follows: diabetic nephropathy in
nine, hypertensive nephrosclerosis in four, chronic
glomerulonephritis in two, others in three, and un-
known in three.
Table 2 Effects of L-carnitine supplementation on nutritional
parameters
Variables Before 3 months 6 months
Laboratory parameters
Blood urea nitrogen (mg/dL) 47.5 ± 15.5 42.9 ± 12.0 45.4 ± 12.7
Creatinine (mg/dL) 6.9 ± 2.8 6.7 ± 2.2 6.6 ± 2.3
Albumin (g/dL) 3.2 ± 0.3 3.1 ± 0.4 3.2 ± 0.4
Transthyretin (mg/dL) 22.4 ± 5.9 22.5 ± 6.5 24.7 ± 9.7
Transferrin (mg/dL) 154.9 ± 40.5 175.5 ± 42.6** 174.9 ± 47.8**
Retinol-binding protein (mg/dL) 8.9 ± 2.5 9.2 ± 2.8 10.0 ± 3.4*
Total lymphocyte count (/μL) 1190 ± 440 1250 ± 610 1150 ± 430
HDL cholesterol (mg/dL) 41 ± 13 44 ± 13 43 ± 14
LDL cholesterol (mg/dL) 73 ± 21 77 ± 27 81 ± 29*
Triglyceride (mg/dL) 91 ± 56 107 ± 81 103 ± 58*
Free fatty acid (mEq/L) 0.2 ± 0.3 0.2 ± 0.2 0.1 ± 0.1
Ceruloplasmin (mg/dL) 22.5 ± 4.9 23.2 ± 10.3 22.6 ± 4.7
Hemoglobin (g/dL) 10.0 ± 1.2 10.2 ± 2.0 10.2 ± 1.7
Ammonia (μg/dL) 21 ± 10 32 ± 10** 36 ± 13**
Nutritional assessment index
GNRI 83.9 ± 7.9 82.3 ± 7.8 82.7 ± 8.8
PNI 38.2 ± 3.7 37.5 ± 4.3 37.3 ± 4.8
nPCR 0.73 ± 0.04 0.66 ± 0.03 0.70 ± 0.04
Kt/V for urea 1.3 ± 0.1 1.3 ± 0.1 1.4 ± 0.1
%CGR 69.5 ± 6.8 65.7 ± 5.5 63.9 ± 5.4
Anthropometric parameters
Dry weight (kg) 48.0 ± 12.5 47.8 ± 12.1 47.7 ± 11.7
BMI (kg/m2) 19.0 ± 3.2 18.9 ± 3.0 18.8 ± 2.9
TMA/TBA ratioa 9.1 ± 3.0 ND 8.8 ± 3.1
Handgrip strength (kg)b 16.0 ± 8.1 ND 16.1 ± 8.6
MAC (cm) 21.8 ± 3.1 ND 23.1 ± 3.8
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L-carnitine supplementation had normalized the serum
total, free, and acylcarnitine levels at 3 months. The total
carnitine levels were increased from 31.1 ± 10.0 to
98.6 ± 27.9 (normal, 45.0–91.0) (p < 0.001), the free
carnitine levels from 19.8 ± 6.6 to 63.3 ± 14.3 (normal,
36.0–76.0) (p < 0.001), and the acylcarnitine levels
from 11.4 ± 4.9 to 35.3 ± 15.9 (normal, 6.0–23.0) μmol/L
(p < 0.001) at 6 months (Fig. 1). However, there was no
difference in free to acylcarnitine ratio between before
(1.92 ± 0.14) and after the treatment (1.98 ± 0.10).
The final dosage of L-carnitine was 191 ± 114 mg/day
(4.0 ± 2.1 mg/kg DW/day). No difference was found in
L-carnitine dosage between HD patients with preserved
residual kidney function (3.8 mg/kg DW/day, n = 7) and
those without (4.5 mg/kg DW/day, n = 14).
Nutritional parameters
Despite the identical DW, significant increases were found
in the serum transferrin (p < 0.01), retinol-blinding protein
(p < 0.05), and triglyceride levels (p < 0.05) (Table 2). In
contrast, GNRI, PNI, nPCR, and %CGR did not change
during the follow-up.
Anthropometric parameters
TSF was significantly increased from 0.4 ± 0.3 to 0.6 ±
0.3 cm (p < 0.05), while MAC and MAMC were not.
There was no difference in the TMA/TBA ratio or hand-
grip strength during the treatment (Table 2). L-carnitine
did not change as to the TMA/TBA ratio in the males
(10.1 ± 3.3 vs. 9.7 ± 3.3) or females (8.0 ± 2.2 vs. 7.8 ± 2.6).
Handgrip strength was also identical between males
(20 ± 6 vs. 21 ± 6 kg) and females (9 ± 6 vs. 8 ± 6 kg).Fig. 1 Changes in serum total, free, and acylcarnitine levels following
the 6-month L-carnitine supplementation. L-carnitine supplementation
for 6 months normalized the total carnitine levels from 31.1 ± 10.0 to
98.6 ± 27.9 (normal, 45.0–91.0), the free carnitine levels from 19.8 ± 6.6
to 63.3 ± 14.3 (normal 36.0–76.0), and the acylcarnitine levels from
11.4 ± 4.9 to 35.3 ± 15.9 (normal, 6.0–23.0) μmol/L
TSF (cm) 0.4 ± 0.3 ND 0.6 ± 0.3*
MAMC (cm) 20.5 ± 3.1 ND 21.3 ± 3.6
BMI body mass index, GNRI geriatric nutritional risk index, PNI prognostic
nutrition index, nPCR normalized protein catabolic rate, Kt/V for urea clearance
of urea normalized to total body water using a single pool model, %CGR
creatinine generation rate, HDL high-density lipoprotein, LDL low-density
lipoprotein, TMA thigh muscle area, TBA thigh bone area, MAC midarm
circumference, TSF triceps skinfold thickness, MAMC midarm muscle
circumference, ND not done, SD standard deviation
*p < 0.05, **p < 0.01 vs. before treatment. Data, means ± SD
aData were available for 20 out of 21 patients
bData were available for 16 out of 21 patientsImmunological and inflammatory markers
A significant increase in NK cell activity was found at
E/T ratio of both 10:1 (10.2 ± 8.8 vs. 12.6 ± 12.4 %;
normal, 8.9–29.5 %) (p < 0.02) and 20:1 (17.2 ± 14.1 vs.
20.8 ± 17.7 %; normal, 17.1–48.7 %) (p < 0.01). In con-
trast, the CD4/CD8 ratio, serum CRP, and soluble
interleukin-2 receptor (sIL-2R) did not change during
the 6-month follow-up. The mean serum IL-6 level
had rather increased from 5.2 ± 2.5 to 7.8 ± 5.1 at
Table 4 Effects of L-carnitine supplementation on cardiac
parameters
Variables Before 6 months
Systolic blood pressure (mmHg) 156.6 ± 3.4 155.0 ± 2.9
Diastolic blood pressure (mmHg) 76.6 ± 3.2 73.4 ± 2.9
Antihypertensive medication
Diuretics (%) 23.8 19.0
α-blocker (%) 4.8 4.8
β-blocker (%) 23.8 23.8
Calcium antagonist (%) 42.9 42.9
Angiotensin II type 1 receptor blocker (%) 47.6 52.4
M-mode echocardiography
EF (%) 69.1 ± 10.8 69.8 ± 10.5
FS (%) 42.2 ± 11.4 46.1 ± 9.8**
LVDd (cm) 4.5 ± 0.9 4.6 ± 0.8
LVDs (cm) 2.6 ± 0.9 2.5 ± 0.8
IVS (mm) 14 ± 3 15 ± 3
LVPW (cm) 1.4 ± 0.2 1.3 ± 0.3
LVM (g) 308.2 ± 131.1 303.5 ± 104.4
LVMI (g/m2) 217.8 ± 100.2 212.3 ± 77.3
Chest X-ray
CTR (%) 52.8 ± 5.3 52.4 ± 5.0
Laboratory data
BNP (pg/mL) 621.4 ± 666.8 412.0 ± 426.0*
EF ejection fraction, FS fractional shortening, LVDd left ventricular end-diastolic
dimension, LVDs left ventricular end-systolic dimension, IVS interventricular
septal thickness, LVPW left ventricular posterior wall end-diastolic thickness,
LVFS left ventricular fractional shortening, LVM left ventricular mass, LVMI left
ventricular mass index, CTR cardiothoracic ratio, BNP: brain natriuretic peptide,
SD standard deviation
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(p = 0.051) (Table 3).
Trace elements
Serum selenium significantly decreased from 60.4 ± 13.9
to 52.4 ± 12.2 μg/L during the follow-up (p = 0.01). The
serum zinc and copper levels did not change (Table 3).
Cardiac parameters
L-carnitine increased as to FS from 42.2 ± 11.4 to 46.1 ±
9.8 % (p < 0.01). There was no difference in the CTR, EF,
and LVMI values between the two measurements. How-
ever, predialysis BNP had significantly decreased from
621.4 ± 666.8 to 412.0 ± 426.0 pg/mL after the 6-month
supplementation (p < 0.02) (Table 4).
Discussion
In this study, we orally administered L-carnitine to
maintain the serum levels of free carnitine within nor-
mal range for 6 months by carefully monitoring and
modifying the dosage during the first 3 months. As a re-
sult, we kept the free carnitine levels within normal
range despite a relatively lower dose (3.8 to 4.5 mg/kg
BW/day) compared to the recommended dosage (5 to
10 mg/kg BW/day).
We also showed that the regimen of L-carnitine supple-
mentation had several beneficial effects on nutritional,
immunological, and cardiac parameters, as follows.
Effects on nutrition
L-carnitine supplementation is reported to improve
nutritional status in HD patients. Oral L-carnitineTable 3 Effects of L-carnitine supplementation on immunological,
inflammatory parameters, and trace elements
Variables Before 3 months 6 months
Immunological and inflammatory
parameters
NK cell activity; E/T ratio 10:1 (%) 10.2 ± 8.8 10.5 ± 9.9 12.6 ± 12.4*
E/T ratio 20:1 (%) 17.3 ± 14.1 17.4 ± 15.3 20.8 ± 17.7**
CD4/CD8 ratio 2.2 ± 3.3 2.0 ± 2.2 2.1 ± 2.3
IgG (mg/dL) 1460 ± 410 1430 ± 350 1490 ± 400
IL-6 (pg/mL) 5.2 ± 2.5 7.8 ± 5.1* 7.7 ± 5.0
sIL-2R (U/mL) 1311 ± 1020 1103 ± 448 1233 ± 498
C-reactive protein (mg/dL) 0.6 ± 1.0 0.6 ± 0.9 1.0 ± 1.8
Trace elements
Selenium (μg/L) 60.4 ± 13.9 63.5 ± 17.0 52.4 ± 12.2*
Zinc (μg/dL) 48.5 ± 8.6 52.3 ± 10.1 51.7 ± 9.6
Copper (μg/dL) 94.0 ± 19.1 90.8 ± 21.9 91.4 ± 23.0
NK cell natural killer cell, E/T ratio effector cells/target cells ratio, CD cluster of
differentiation, IgG immunoglobulin G, IL-6 interleukin-6, sIL-2R soluble
interleukin-2 receptor, SD standard deviation
*p < 0.05, **p < 0.01 vs. before treatment. Data, means ± SD
*p < 0.05, **p < 0.01 vs. before treatment. Data, means ± SDadministration increased nPCR independently of dialysis
dose [12]. L-carnitine also improved nutritional parame-
ters such as serum transferrin and albumin in HD pa-
tients [13, 14]. Intravenous administration of L-carnitine
(2 g) at the end of a HD session also increases the
morphological diameters of skeletal muscle fibers [15].
L-carnitine treatment prevented deterioration of the
peak rate of oxygen consumption (VO2 max) [16].
In this study, L-carnitine significantly increased serum
retinol-binding protein and transferrin 6 months later.
In addition, the treatment increased serum ammonia
despite within the normal range, indicating a possibility
that L-carnitine may enhance ammonia production via
urea cycle by increased food intake. However, nPCR, an
indirect marker of dietary protein intake, remained lower
during the study. L-carnitine also did not improve other
nutritional parameters such as GNRI and PNI. There
was no difference in muscle mass area, handgrip power,
and %CGR. These findings convincingly suggest that
oral L-carnitine treatment for 6 months to maintain
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viate poor nutritional status.
In contrast, TSF was significantly increased after the
treatment. However, since TMA/TBA ratio, a marker of
thigh skeletal mass area, was rather decreased from
9.1 ± 3.0 to 8.8 ± 3.1 despite no gain of body weight,
it might be explained by the changes in regional body
composition due to progressive sarcopenia at the
upper arm.
Effects on immune response
NK cells activity plays an important role in the defense
mechanism against infections and tumors. In HD pa-
tients, the activity of NK cells is either lowered or un-
changed [17]. A higher CD4/CD8 ratio, a marker of Ig
production by B cells, is also associated with a better
serological response to hepatitis B vaccination [18].
L-carnitine can restore the age-related changes in neu-
trophil function such as chemotactic and phagocytic ac-
tivity in vitro [19]. L-carnitine treatment also prevented
agent-induced experimental colitis by abrogation of both
innate and adaptive immune responses in mice [20]. In
addition, L-carnitine can reduce the apoptotic levels of
CD4+ and CD8+ cells [21].
In the present study, L-carnitine supplementation sig-
nificantly increased NK cell activity at E/T ratios of 10:1
and 20:1, but it first became evident at 6 months. So, at
least more than 3 months will be needed to restore NK
cell activity following L-carnitine therapy. Selenium defi-
ciency is potentially associated with cellular immunity in
HD patients [17]. However, serum selenium was rather
decreased from 60.4 ± 13.9 to 52.4 ± 12.2 μg/L after the
supplementation, suggesting no association of selenium
deficiency with restored NK cell activity.
Effects on cardiac parameters
L-carnitine prevents the development of ventricular fi-
brosis and heart failure with preserved EF in hyperten-
sive heart disease [22]. L-carnitine also blocks dietary
vitamin B deficiency-induced left ventricular dysfunction
and attenuates the diet-caused increase in serum BNP
[23]. In patients with chronic heart failure, the plasma
carnitine levels are correlated with %FS, EF, and LVMI
[24]. A meta-analysis also revealed that L-carnitine is as-
sociated with a 27 % reduction in all-cause mortality and
a 40 % reduction in angina symptoms in patients experi-
encing acute myocardial infarction [25].
It has been reported that oral L-carnitine treatment
significantly improved left ventricular function [26, 27],
while it reduced LVMI [28]. In this study, we confirmed
that L-carnitine supplementation caused a significant in-
crease in %FS concomitantly with a reduction of BNP.
In contrast, L-carnitine did not change LVMI. The rea-
son for this discrepancy remains unknown, but it maybe partly due to the shorter period of supplementation
than in the previous study (12 months) [28].
Effects on inflammation
A link between inflammation and carnitine deficiency
has been well suggested in HD patients. However, the
results of the recent two meta-analysis studies involv-
ing randomized controlled trials did not coincide; one
study [29] showed that L-carnitine significantly de-
creased serum CRP, whereas the other disclosed no
effect [30].
In this study, oral L-carnitine did not change the
serum CRP level, while it rather increased the serum
IL-6 level after 6 months. Because it is reported that
oral administration of 1000 mg/kg BW of L-carnitine
decreased serum CRP and IL-6 [31, 32], a higher dose
may be required to alleviate the uremia-related in-
flammatory response.
Study limitations
There are several limitations to this study. Firstly, this
study was not carried out in a randomized controlled
manner, and the number of patients was clearly small.
So, future studies involving more samples are needed to
confirm the association of L-carnitine treatment and
clinical parameters. Secondly, we simply compared a lot
of clinical markers before and after L-carnitine treat-
ment. So, it remains unknown whether or not these im-
munological and echocardiographic alterations may lead
to beneficial effects on clinical outcomes. Thirdly, since
we administered L-carnitine orally at a relatively low
dose, its effect may be limited compared to intravenous
administration. Fourthly, we did not measure the appen-
dicular skeletal mass index using bioelectrical impedance
(BIA) or dual-energy X-ray absorptiometry, so we could
not precisely confirm the presence of sarcopenia. Finally,
muscle atrophy progresses over time, so it will be neces-
sary to evaluate the effect of L-carnitine in the long
term.
Conclusions
We showed that L-carnitine supplementation had sev-
eral effects on clinical parameters. L-carnitine increased
NK cell activity following the 6-month treatment. There
was a significant increase in %FS with a decrease in
BNP. The findings suggested that L-carnitine can im-
prove immunological and LV-related systolic func-
tional parameters. In contrast, L-carnitine did not
ameliorate sarcopenic markers and did not reduce the
inflammatory response. So, future well-designed RCT
is obviously needed to confirm the multidirectional
actions of L-carnitine supplementation in patients on
regular HD.
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